Search

Search Constraints

You searched for: Author/Creator Noviello, Stephanie

Search Results

1. 821Daclatasvir and Asunaprevir Plus Peginterferon Alfa-2a and Ribavirin in Patients With HCV Genotype 1 or 4 Infection: Phase 3 HALLMARK-QUAD Results. (December 2014)

2. A pooled analysis of patients with wound infections in the Phase 3 REVIVE trials: randomized, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin structure infections. Issue 4 (20th March 2020)

3. All‐oral daclatasvir plus asunaprevir for chronic hepatitis C virus (HCV) genotype 1b infection: a sub‐analysis in Asian patients from the HALLMARK DUAL study. (28th April 2016)

5. Daclatasvir + sofosbuvir versus standard of care for hepatitis C genotype 3: a matching-adjusted indirect comparison. (March 2016)

6. Daclatasvir + sofosbuvir versus standard of care for hepatitis C genotype 3: a matching-adjusted indirect comparison. (March 2016)

7. Daclatasvir + sofosbuvir versus standard of care for hepatitis C genotype 3: a matching-adjusted indirect comparison. (March 2016)

8. Daclatasvir and Sofosbuvir with Ribavirin for 24 Weeks in Chronic Hepatitis C Genotype-3-Infected Patients with Cirrhosis: A Phase III Study (ALLY-3C). Issue 1 (January 2019)

9. Daclatasvir plus asunaprevir for HCV genotype 1b infection in patients with or without compensated cirrhosis: a pooled analysis. (24th January 2016)

10. Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study. Issue 6 (30th July 2014)